Iovance Biotherapeutics Class Action Lawsuit
Analysis based on 14 articles · First reported May 19, 2025 · Last updated Jun 17, 2025
The class action lawsuit against Atara Biotherapeutics could lead to a decline in its stock price due to potential financial liabilities and negative investor sentiment. For the broader biotechnology market, it highlights the importance of transparent communication and accurate financial reporting.
Rosen Law Firm has filed a class action lawsuit against Atara Biotherapeutics, alleging that the company made false and misleading statements to investors between May 9, 2024, and May 8, 2025. The lawsuit claims that Atara Biotherapeutics failed to disclose issues with its Authorized Treatment Centers (ATCs) experiencing longer timelines for patient treatment with Amtagvi, and that its sales team and ATCs were ineffective in patient identification and selection, leading to higher patient drop-offs. These dynamics allegedly resulted in increased costs and lower revenue for Atara Biotherapeutics, as ATCs could not keep pace with manufactured product. Investors who purchased Atara Biotherapeutics securities during the specified period are encouraged to join the class action by the July 14, 2025, lead plaintiff deadline.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard